Exploratory analyses from the VE303 Phase 2 CONSORTIUM study identify statistically significant relationships between VE303 bacterial species and multiple parameters that...

Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer and inflammatory diseases based on its unique Mimicry platform, announces the...

Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that it has...

MaaT Pharma (EURONEXT), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival...

Microbiotica, a leader in discovering and developing microbiome-based therapeutics and biomarkers, today announces it has entered into a clinical trial collaboration with MSD...

Cerea Partners, the investor-partner of the food & beverage universe companies, has entered into exclusive negotiations with a view to acquire a majority stake of Polaris...

Collaboration joins MD Anderson's expertise and capabilities with Fed Bio's proprietary ACT bacterial cell therapy platform to design and manufacture a complex, synthetic...